Adjuvant vinorelbine plus cisplatin extended survival longer than observation in resected non–small-cell lung cancer at median 76 months

摘要

The study by Douillard and colleagues confirms the findings from anrecent randomized trial (1) showing that adjuvant chemotherapynimproves survival for completely resected NSCLC. This treatmentnshould now be considered the standard of care.